BACKGROUND: There are few sex-specific outcome data in heart failure with preserved ejection fraction. METHODS AND RESULTS: We assessed sex differences in baseline characteristics and outcomes among 4128 patients with heart failure with preserved ejection fraction in the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Women (n=2491) with heart failure with preserved ejection fraction were ≈1 year older (72±7 years versus 71±7 years) and more likely to be obese (46% versus 35%) and have chronic kidney disease (34% versus 26%) and hypertension (91% versus 85%) than men but less likely to have an ischemic cause (19% versus 34%), atrial fibrillation (27% versus 33%), or chronic obstructive pulmonary disease (8% versus 13%) (all P<0.001). During a mean of 49.5 months, there were 881 deaths (447 in women, 434 in men; risk ratio, 0.64; 95% CI, 0.56-0.74) and 5776 hospitalizations (3239 in women, 2537 in men; risk ratio, 0.80; 95% CI, 0.76-0.84). Women had lower risk of all-cause events (deaths and hospitalizations), even after adjusting for baseline characteristics (adjusted hazards ratio, 0.81; 95% CI, 0.73-0.89). However, the sex-related difference in risk of all-cause events was modified in the presence or absence of atrial fibrillation, renal dysfunction, stable angina pectoris, or advanced New York Heart Association class symptoms. CONCLUSIONS: In patients with typical heart failure with preserved ejection fraction, there were prominent sex differences in baseline characteristics and outcomes. Women had better overall prognosis, although the presence of 4 common baseline characteristics seemed to moderate this finding.
BACKGROUND: There are few sex-specific outcome data in heart failure with preserved ejection fraction. METHODS AND RESULTS: We assessed sex differences in baseline characteristics and outcomes among 4128 patients with heart failure with preserved ejection fraction in the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Women (n=2491) with heart failure with preserved ejection fraction were ≈1 year older (72±7 years versus 71±7 years) and more likely to be obese (46% versus 35%) and have chronic kidney disease (34% versus 26%) and hypertension (91% versus 85%) than men but less likely to have an ischemic cause (19% versus 34%), atrial fibrillation (27% versus 33%), or chronic obstructive pulmonary disease (8% versus 13%) (all P<0.001). During a mean of 49.5 months, there were 881 deaths (447 in women, 434 in men; risk ratio, 0.64; 95% CI, 0.56-0.74) and 5776 hospitalizations (3239 in women, 2537 in men; risk ratio, 0.80; 95% CI, 0.76-0.84). Women had lower risk of all-cause events (deaths and hospitalizations), even after adjusting for baseline characteristics (adjusted hazards ratio, 0.81; 95% CI, 0.73-0.89). However, the sex-related difference in risk of all-cause events was modified in the presence or absence of atrial fibrillation, renal dysfunction, stable angina pectoris, or advanced New York Heart Association class symptoms. CONCLUSIONS: In patients with typical heart failure with preserved ejection fraction, there were prominent sex differences in baseline characteristics and outcomes. Women had better overall prognosis, although the presence of 4 common baseline characteristics seemed to moderate this finding.
Authors: Lilian Grigorian-Shamagian; Fernando Otero Raviña; Emad Abu Assi; Rafael Vidal Perez; Elvis Teijeira-Fernandez; Alfonso Varela Roman; Laura Moreira Sayagues; Jose Ramon Gonzalez-Juanatey Journal: Am Heart J Date: 2008-11-08 Impact factor: 4.749
Authors: R B Devereux; M J Roman; J E Liu; T K Welty; E T Lee; R Rodeheffer; R R Fabsitz; B V Howard Journal: Am J Cardiol Date: 2000-11-15 Impact factor: 2.778
Authors: D W Kitzman; J M Gardin; J S Gottdiener; A Arnold; R Boineau; G Aurigemma; E K Marino; M Lyles; M Cushman; P L Enright Journal: Am J Cardiol Date: 2001-02-15 Impact factor: 2.778
Authors: Kirsten Bibbins-Domingo; Feng Lin; Eric Vittinghoff; Elizabeth Barrett-Connor; Deborah Grady; Michael G Shlipak Journal: J Am Coll Cardiol Date: 2004-10-19 Impact factor: 24.094
Authors: Jeptha P Curtis; Seth I Sokol; Yongfei Wang; Saif S Rathore; Dennis T Ko; Farid Jadbabaie; Edward L Portnay; Stephen J Marshalko; Martha J Radford; Harlan M Krumholz Journal: J Am Coll Cardiol Date: 2003-08-20 Impact factor: 24.094
Authors: Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren Journal: Lancet Date: 2003-09-06 Impact factor: 79.321
Authors: Eileen O'Meara; Tim Clayton; Margaret B McEntegart; John J V McMurray; Ileana L Piña; Christopher B Granger; Jan Ostergren; Eric L Michelson; Scott D Solomon; Stuart Pocock; Salim Yusuf; Karl Swedberg; Marc A Pfeffer Journal: Circulation Date: 2007-06-11 Impact factor: 29.690
Authors: Emily S Lau; Samantha M Paniagua; James Sawalla Guseh; Vijeta Bhambhani; Markella V Zanni; Paul Courchesne; Asya Lyass; Martin G Larson; Daniel Levy; Jennifer E Ho Journal: J Am Coll Cardiol Date: 2019-09-24 Impact factor: 24.094
Authors: Bharathi Upadhya; Michael Rocco; Cora E Lewis; Suzanne Oparil; Laura C Lovato; William C Cushman; Jeffrey T Bates; Natalie A Bello; Gerard Aurigemma; Lawrence J Fine; Karen C Johnson; Carlos J Rodriguez; Dominic S Raj; Anjay Rastogi; Leonardo Tamariz; Alan Wiggers; Dalane W Kitzman Journal: Circ Heart Fail Date: 2017-04 Impact factor: 8.790
Authors: Charles B Eaton; Mary Pettinger; Jacques Rossouw; Lisa Warsinger Martin; Randi Foraker; Abdullah Quddus; Simin Liu; Nina S Wampler; Wen-Chih Hank Wu; JoAnn E Manson; Karen Margolis; Karen C Johnson; Matthew Allison; Giselle Corbie-Smith; Wayne Rosamond; Khadijah Breathett; Liviu Klein Journal: Circ Heart Fail Date: 2016-10 Impact factor: 8.790